Assignee
SUZHOU TRANSCENTA THERAPEUTICS CO LTD
CN·1 granted patent·9 pending applications·0 citations·filing 2020–2023
Top patents by PatentIndex Score
10 records- 0155US2025282874A1Bifunctional protein, and preparation thereof and use thereofSUZHOU TRANSCENTA THERAPEUTICS CO LTD·Filed 2023·Application pending·0 cites
- 0254US2025326834A1Combination therapy of claudin 18.2 antagonist and pd-1/pd-l1 axis inhibitorSUZHOU TRANSCENTA THERAPEUTICS CO LTD·Filed 2022·Application pending·0 cites
- 0352US11753473B2Anti-PD-L1 antibodiesSUZHOU TRANSCENTA THERAPEUTICS CO LTD·Filed 2020·Granted Sep 12, 2023·0 cites·28 claims
- 0452US2024309113A1Novel anti-masp-2 antibodiesSUZHOU TRANSCENTA THERAPEUTICS CO LTD·Filed 2022·Application pending·0 cites
- 0550US2024043566A1Bi-functional moleculesSUZHOU TRANSCENTA THERAPEUTICS CO LTD·Filed 2021·Application pending·0 cites
- 0650US2024307564A1Anti-cldn18.2 antibody conjugatesSUZHOU TRANSCENTA THERAPEUTICS CO LTD·Filed 2022·Application pending·0 cites
- 0748US2024294622A1Novel anti-gremlin1 antibodiesSUZHOU TRANSCENTA THERAPEUTICS CO LTD·Filed 2022·Application pending·0 cites
- 0847US2023331836A1Anti-cldn18.2 antibodies and diagnostic uses thereofSUZHOU TRANSCENTA THERAPEUTICS CO LTD·Filed 2021·Application pending·0 cites
- 0945US2024209099A1Novel anti-hvegfr2 antibodiesSUZHOU TRANSCENTA THERAPEUTICS CO LTD·Filed 2022·Application pending·0 cites
- 1042US2022306765A1Novel anti-cldn18.2 antibodiesSUZHOU TRANSCENTA THERAPEUTICS CO LTD·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when SUZHOU TRANSCENTA THERAPEUTICS CO LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →